Phase II Vanguards data visualization tool provides oversight of groundbreaking investigational new drugs and under-the-radar institutions developing them.
Explore the intricate balance between economy and well-being. Discover how country's GDP and health expenditure influence core health outcomes.
In a fast-changing pharma landscape, our MyRBQM® Portal transforms clinical trial and pipeline oversight and aids in M&A due diligence, offering a strategic edge in compliance and growth.
Explore how Vanguard companies, innovative small pharma entities, differ in research focus and recruitment dynamics from larger Pharma.
Enhancing Clinical Trial Risk Management: A Response to the Growing Concerns over Fraudulent Studies
In this blog, we explore the growing concerns about fraudulent RCTs highlighted in a recent Nature article. Discover how innovative risk management approaches can detect, prevent, and tackle these issues, facilitating more robust regulatory oversight.
MyRBQM Portal has made its debut on the Azure Marketplace. This milestone allows biopharmaceutical companies to streamline and unify their approach to risk management by using the secure and reliable Azure cloud platform.
How heavily do decentralized clinical trials rely on technology? We asked Craig Lipset, a leading expert in the field of decentralized clinical trials.
Discover how Decentralized Clinical Trials (DCTs) have the potential to reshape oncology care. Using our eyesON DCT Outlook, we reveal how patient demographics, broadband internet, and registered oncologists could drive DCT opportunities and potentially enhance cancer survivorship.
Data visualization tool designed to identify untapped opportunities for Decentralized Clinical Trials advancement in the oncology sector in the USA.
Be prepared for ICH E6(R3): turn guidelines into real-world action. In this post, we delve into the key updates and training gaps.